Compare IDN & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDN | ONCY |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 98.7M |
| IPO Year | 2014 | 2002 |
| Metric | IDN | ONCY |
|---|---|---|
| Price | $4.12 | $0.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $7.33 | $7.33 |
| AVG Volume (30 Days) | 417.1K | ★ 1.7M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $4,433,454.00 | N/A |
| Revenue This Year | $12.54 | N/A |
| Revenue Next Year | $15.32 | $2,505.00 |
| P/E Ratio | $136.33 | ★ N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $3.95 | $0.56 |
| 52 Week High | $9.08 | $1.51 |
| Indicator | IDN | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 32.03 | 57.54 |
| Support Level | $3.99 | $0.94 |
| Resistance Level | $5.07 | $1.14 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 24.14 | 45.19 |
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.